BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.
BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.
Current Team (4)Update
Past Team (3)Update
Funding Rounds (4) - $73MUpdate
BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and...
Early-Stage Biotech investment
PolyTechnos Venture-Partners nurtures technological innovation and guides exceptional...
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
Asset Management Company is a Silicon Valley venture capital firm. Since 1965, the company has...
IT and Healthcare VC
Vulcan Capital invests across all stages of corporate development through leveraged buyouts,...
Lighthouse Capital Partners is the leading venture debt firm, providing capital to early- and...
1000 Marina Blvd.
Brisbane, CA 94005